Tamoxifen therapy in patients with recurrent laryngeal squamous carcinoma. 1990

S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.

Twelve patients with recurrent, advanced laryngeal carcinoma were treated with tamoxifen hormonal therapy. Rationale was based on previous in vitro data identifying estrogen receptors and progesterone receptors in some laryngeal carcinoma cell lines. Four patients received tamoxifen, 10 to 20 mg by mouth twice a day; eight received 40 mg by mouth four times a day. The drug was well tolerated at all dose levels. There were no clinical responses. Two patients' tumor tissue was assayed for estrogen and progesterone receptors. One was negative for both, and the other was indeterminate for estrogen receptors and negative for progesterone receptors. A review of literature and a discussion of the possible reasons for the negative results are presented.

UI MeSH Term Description Entries
D007822 Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS. Cancer of Larynx,Laryngeal Cancer,Larynx Neoplasms,Cancer of the Larynx,Larynx Cancer,Neoplasms, Laryngeal,Cancer, Laryngeal,Cancer, Larynx,Cancers, Laryngeal,Cancers, Larynx,Laryngeal Cancers,Laryngeal Neoplasm,Larynx Cancers,Larynx Neoplasm,Neoplasm, Laryngeal,Neoplasm, Larynx,Neoplasms, Larynx
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
August 2016, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
June 1987, Gynecologic oncology,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
January 1989, Gynecologic oncology,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
September 1998, Cancer,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
July 2001, Head & neck,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
February 2019, Head & neck,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
January 2007, ORL; journal for oto-rhino-laryngology and its related specialties,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
January 2009, Otolaryngologia polska = The Polish otolaryngology,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
June 2019, Ear, nose, & throat journal,
S G Urba, and T E Carey, and V Kudla-Hatch, and G T Wolf, and A A Forastiere
October 2016, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale,
Copied contents to your clipboard!